Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 28
Biopharm constitutes 16% of Novo Nordisk sales and a
strategy has been defined to return to growth
DKK
billion
6
5
4
3
2
1
0
NovoSevenⓇ and Norditropin®
account for 82% of Biopharm sales¹
Other biopharmaceuticals
Other haemophilia products
NorditropinⓇ
NovoSevenⓇ
'Return to Growth' strategy builds on organic,
non-organic and organisational initiatives
Return to
growth
in Biopharm
Drive in-market brands beyond
current plans and ensure
successful pipeline launches
Pursue licensing or acquisition of
complementary assets or
companies
Strengthen the organisation to
drive the Biopharm return to
growth agenda
Q2
2013
1 Reported sales for the first six months of 2018
changing
diabetes
Q2
2018
novo nordiskView entire presentation